Clinical trial NCT00988559: Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
Official title: A Pilot Study of pnGVL4a-CRT/E7 (Detox) for the Treatment of Patients With HPV16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: HPV16 Positive
Cervical Intraepithelial Neoplasia (CIN 2/3)
Keywords: high grade cervical dysplasia
treatment vaccine
therapeutic
HPV
DNA vaccine
gene therapy
gene gun
pre-cancerous
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
name: National Cancer Institute (NCI)
First posted: 2009-10-02
Enrollment: 132
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will test the efficacy and safety of different routes of administration of a DNA vaccine in patients with HPV16+ CIN2/3. Subjects will be enrolled in one of six treatment groups. Subjects enrolled in the first two groups will receive vaccination intradermally with a needle-free delivery device. Subjects enrolled in groups 3 and 4 will receive vaccination intramuscularly. Subjects enrolled in groups 5 and 6 will receive vaccine intralesionally.

Detailed description: Primary Objectives

* To evaluate the feasibility and toxicity of vaccination in women with CIN2/3 caused by HPV16
* To evaluate the effect of vaccination on histology
* To compare immunogenicity of three different routes of administration: intradermal (ID), intramuscular (IM), intralesional (IL).

Secondary Objectives:

* To evaluate changes in HPV viral load
* To evaluate the cellular immune response to vaccination
* To evaluate the humoral immune response to vaccination
* To evaluate local tissue immune response
* To correlate measures of immune response with clinical response
* To correlate measures of immune response with those observed in the preclinical model

Eligibility criteria: Inclusion Criteria:

* patients with high grade cervical intraepithelial lesions (CIN2/3)
* patients whose lesions are HPV16+
* patients who are age 18 or older
* patients who are able to give informed consent
* patients who are immunocompetent
* patients who are not pregnant, committed to using adequate contraception if of childbearing age
* patients who have a minimum hemoglobin level of 9

Exclusion Criteria:

* Patients with cytologic evidence of glandular dysplasia
* Patients with cytologic evidence of adenocarcinoma in situ
* Patients who are pregnant
* Patients with an active autoimmune disease
* Patients who are taking immunosuppressive medication
* Patients with concurrent malignancy except for nonmelanoma skin lesions
* Patients who have an allergy to gold.
* Patients with any evidence of damaged skin, or moles, scars, tattoos or marks at the proposed site(s) of administration that might interfere with the interpretation of local skin reactions.
* History or evidence of a physician-diagnosed chronic or recurrent inflammatory skin disease (e.g. psoriasis, eczema, atopic dermatitis, hypersensitivity) at the proposed site of administration in the past 5 years.
* Patients who have an active autoimmune disease or history of autoimmune disease requiring medical treatment with systemic immunosuppressants, including: inflammatory bowel disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemic, or immune thrombocytopenia, rheumatoid arthritis, SLE, and Sjogren's syndrome, sarcoidosis. Asthma or COPD that does not require systemic corticosteroids or routine use of inhaled steroids is acceptable
* Patients who have received prior chrysotherapy (administration of gold salts to treat rheumatoid arthritis).
* Patients with a history of arterial or venous thrombosis
* Patients with non-healed wounds.
* Patients with a history of keloid formation ( ID delivery group only)
* Patients with a history of hepatitis B with persistent infection.

Primary outcomes:
measure: Number of Participants With Related Serious Adverse Events
timeFrame: 9 months
Secondary outcomes:
measure: Absence of CIN2/3 Lesion by Week 15
timeFrame: 15 weeks
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
city: Baltimore
country: United States
facility: Johns Hopkins Outpatient Center
state: Maryland
city: Baltimore
country: United States
facility: Johns Hopkins Bayview Medical Center
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Cornelia L Trimble, MD
role: PRINCIPAL_INVESTIGATOR
References: